Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
about
The effects of microRNA on the absorption, distribution, metabolism and excretion of drugsComputational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and softwareDetection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism.In vitro characterization of potential CYP- and UGT-derived metabolites of the psychoactive drug 25B-NBOMe using LC-high resolution MS.Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1.Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.Detection of nanolevel drug metabolites in an organotypic culture of primary human hepatocytes and porcine hepatocytes with special reference to a two-compartment model.Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.Bioavailability of phytochemicals and its enhancement by drug delivery systems.Modeling bioavailability to organs protected by biological barriers.Drug metabolism and drug interactions: potential application to antituberculosis drugs.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.Metabolic difference of CZ48 in human and mouse liver microsomes.Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability.Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human.Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1.Synthesis and Determination of Lipophilicity, Anticonvulsant Activity, and Preliminary Safety of 3-Substituted and 3-Unsubstituted N-[(4-Arylpiperazin-1-yl)alkyl]pyrrolidine-2,5-dione Derivatives.Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors.
P2860
Q26822987-0A638C10-1997-4F78-BF92-00E9844D459DQ28659783-8B41515B-0D51-495E-A211-E10A0DAA9DD1Q31133258-8702D30C-07DC-4897-A403-F68F1387AEFAQ35779974-2E7E1E5C-8C7F-41F1-907F-BBC04BEB77F4Q36115752-90ACDC82-74D6-468A-8C91-16EA7A423CBDQ36132276-B2DAD847-7877-4EA6-A1CF-6D7D724ACCF7Q36132293-D4CE1D00-26EF-4849-9E7D-5CE66F595376Q36440758-4EFBA716-94BE-4744-B1A0-063C5C2A29EAQ37975545-2A0AF1C3-B230-4A73-9791-F934BC2C13BFQ38017309-4318AB60-6BB7-4DCD-BC03-E5F3C215B5CBQ38084084-14720D3A-BE0B-4C22-8D72-85E6E0B1D737Q38288015-B2EBDB0D-C8D7-4BA0-A5D2-B5993905083BQ38502286-4A9249FC-8A22-49E9-B9AA-ED9387FA70FEQ38798449-361E97D2-2ADF-4C16-B13B-952B3A7928A0Q39636097-A7FFBE02-0C68-4E9B-8E2E-65C92DA3FF47Q41855283-68C973F5-7E9B-438F-8C69-44E360FC58AAQ43779543-9F221584-B6A2-494E-A7FB-DE1D28B98972Q45929272-252740B4-B5A6-44B6-A424-4B979AE59683Q46715656-C87EC87C-95C9-4718-8E86-4B0D9431B3DFQ47633070-300EDA96-1746-490F-8873-04CB823A5CA9Q47943718-072DDACF-DB02-4758-B29F-8D30EABC46E3
P2860
Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Methodologies for investigatin ...... earance and P450 contribution.
@en
Methodologies for investigatin ...... earance and P450 contribution.
@nl
type
label
Methodologies for investigatin ...... earance and P450 contribution.
@en
Methodologies for investigatin ...... earance and P450 contribution.
@nl
prefLabel
Methodologies for investigatin ...... earance and P450 contribution.
@en
Methodologies for investigatin ...... earance and P450 contribution.
@nl
P1476
Methodologies for investigatin ...... learance and P450 contribution
@en
P2093
Amin Rostami-Hodjegan
Norie Murayama
P304
P356
10.2174/138920010794233503
P407
P577
2010-10-01T00:00:00Z